Management of patients with acute coronary syndromes: What is the clinical role of direct thrombin inhibitors?

Drugs

Volumn 62, Issue 13, 2002, Pages 1839-1852

  Eikelboom, John W ^a   French, John ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Green Lane Hospital   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; EFEGATRAN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; STREPTOKINASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CORONARY DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBIN; TREATMENT OUTCOME;

ANGINA;

EID: 0036384079     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262130-00001     Document Type: Review

References (57)

1. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50
2. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in unstable angina and non-q-wave myocardial infarction (NQMI): a meta-analysis. Lancet 2000; 355: 1936-42
3. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
4. Weitz JI. Biologic rationale for the therapeutic role of specific antithrombins. Coron Artery Dis 1996; 7: 409-19
5. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82: 12P-18P
6. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-84
7. Direct Thrombin Inhibitor Trialists' Collaborative group. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: Design of a meta-analysis based on individual patient data. Am Heart J 2001; 141: E2-9
8. HERO-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358: 1855-63
9. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
10. Toschi V, Lettino M, Gallo R, et al. Biochemistry and biology of hirudin. Coron Artery Dis 1996; 7: 420-8
11. Zoldhelyi P, Webster MWI, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effects on coagulation parameters. Circulation 1993; 88: 2015-22
12. Verstraete M. Modulating platelet function with direct thrombin inhibitors. Haemostasis 1996; 26: 70-7
13. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996; 22: 185-96
14. Tripodi A, Chantarangkul V, Arbini AA, et al. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70: 286-8
15. Potzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: assessment of whole blood ecarin clotting time. Thromb Haemost 1997; 77: 920-5
16. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202
17. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterisation of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101
18. Witting JI, Bourdon P, Brezniak DV, et al. Thrombin-specific inhibition by and slow cleavage of Hirulog-1. Biochem J 1992; 283: 737-43
19. Ren S, Fenton II JW, Maraganore JM, et al. Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin. Cardiovasc Pharmacol 1997; 29: 337-42
20. Kranzhofer R, Maraganore JM, Baciu R, et al. Systemic thrombin inhibition by Hirulog does not alter medial smooth muscle cell proliferation and inflammatory activation after vascular injury in the rabbit. Cardiovasc Drugs Ther 1999; 13: 429-34
21. Burchenal JE, Marks DS, Mann JT, et al. Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am J Cardiol 1998; 82: 511-5
22. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63
23. Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996; 7: 438-48
24. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000; 12 Suppl. F: 33F-6
25. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107
26. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996; 7: 455-8
27. McKeage K, Plosker GL. Argatroban. Drugs 2001; 61 (4): 515-22
28. Uriuda Y, Wang Q-D, Grip L, et al. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed chest porcine model of coronary artery thrombosis. Cardiovasc Res 1996; 32: 320-7
29. Shuman RT, Rothenberger RB, Campbell CS, et al. Highly selective tripeptide thrombin inhibitors. J Med Chem 1993; 36: 314-9
30. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21
31. Organisation to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation 1997; 96: 769-77
32. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-38
33. Klootwijk P, Lenderink T, Meij S, et al. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Eur Heart J 1999; 20: 1101-11
34. TRIM Investigators. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J 1997; 18: 1416-25
35. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin vs recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7
36. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82
37. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90: 1624-30
38. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21
39. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Circulation 1994; 90: 1638-42
40. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (Lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999; 34: 966-73
41. Kaplinsky E. Direct antithrombin-argatroban in acute myocardial infarction (ARGAMI-2). In: Alderman J, editor. Late breaking clinical trials. J Am Coll Cardiol 1998; 32: 1-7
42. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog vs heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997; 96: 2155-61
43. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333: 757-63
44. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-9
45. Metz BK, White HD, Granger CB, et al. for the GUSTO-IIb investigators. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. J Am Coll Cardiol 1998; 31: 1493-8
46. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13
47. Mehta S, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus vs infusion thrombolytic therapy: a meta-analysis of over 100,000 patients. Lancet 2000; 356: 449-54
48. Mehta S, Eikelboom JW, Natarajan M, et al. Early percutaneous coronary intervention in hirudin and unfractionated heparin-treated patients with acute coronary syndromes. Eur Heart J. In press
49. Roe MT, Granger CB, Ohman EM, et al. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes [abstract]. J Am Coll Cardiol 2000; 35: 39A
50. Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Am J Cardiol 1998; 82: 43P-9P
51. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin vs heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9
52. Kleiman NS, Lincoff AM, Harrington RA, et al. Antithrombin, antiplatelet therapy or both during PCI: a preliminary randomized trial. J Am Coll Cardiol 2001: 37 Suppl. A; 77A
53. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abcixcmab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-53
54. Direct Thrombin Inhibitor Trialists' Collaborative group. Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data. Lancet 2002; 359: 294-302
55. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. N Engl J Med 2001; 345: 494-502
56. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35
57. The Medicines Company. REPLACE Study-Angiomax® in the modern PCI setting [online]. Available from URL: http://www.themedicinescompany.com/[Accessed 2002 Jan 22]